Latest information on Circulating Tumor Cell (CTC) technology for clinical cancer management
Pages
▼
Saturday, April 19, 2014
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
No comments:
Post a Comment